Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer.

Details

Ressource 1Download: BIB_18BCB16AF802.P001.pdf (1415.20 [Ko])
State: Public
Version: author
Serval ID
serval:BIB_18BCB16AF802
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer.
Journal
Chinese journal of cancer
Author(s)
Qiu B., Ding P.R., Cai L., Xiao W.W., Zeng Z.F., Chen G., Lu Z.H., Li L.R., Wu X.J., Mirimanoff R.O., Pan Z.Z., Xu R.H., Gao Y.H.
ISSN
1944-446X (Electronic)
ISSN-L
1944-446X
Publication state
Published
Issued date
2016
Peer-reviewed
Oui
Volume
35
Number
1
Pages
65
Language
english
Abstract
BACKGROUND: Complete resection of locally advanced sigmoid colon cancer (LASCC) is sometimes difficult. Patients with LASCC have a dismal prognosis and poor quality of life, which has encouraged the evaluation of alternative multimodality treatments. This prospective study aimed to assess the feasibility and efficacy of neoadjuvant chemoradiotherapy (neoCRT) followed by surgery as treatment of selected patients with unresectable LASCC.
METHODS: We studied the patients with unresectable LASCC who received neoCRT followed by surgery between October 2010 and December 2012. The neoadjuvant regimen consisted of external-beam radiotherapy to 50 Gy and capecitabine-based chemotherapy every 3 weeks. Surgery was scheduled 6-8 weeks after radiotherapy.
RESULTS: Twenty-one patients were included in this study. The median follow-up was 42 months (range, 17-57 months). All patients completed neoCRT and surgery. Resection with microscopically negative margins (R0 resection) was achieved in 20 patients (95.2%). Pathologic complete response was observed in 8 patients (38.1%). Multivisceral resection was necessary in only 7 patients (33.3%). Two patients (9.5%) experienced grade 2 postoperative complications. No patients died within 30 days after surgery. For 18 patients with pathologic M0 (ypM0) disease, the cumulative probability of 3-year local recurrence-free survival, disease-free survival and overall survival was 100.0%, 88.9% and 100.0%, respectively. For all 21 patients, the cumulative probability of 3-year overall survival was 95.2% and bladder function was well preserved.
CONCLUSION: For patients with unresectable LASCC, preoperative chemoradiotherapy and surgery can be performed safely and may result in an increased survival rate.
Pubmed
Open Access
Yes
Create date
19/07/2016 17:59
Last modification date
20/08/2019 12:49
Usage data